NASDAQ:BDRX Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis $0.46 -0.06 (-12.13%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.46 0.00 (-0.04%) As of 10/9/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Biodexa Pharmaceuticals Stock (NASDAQ:BDRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BDRX alerts:Sign Up Key Stats Today's Range$0.45▼$0.5250-Day Range$0.46▼$1.6052-Week Range$0.45▼$52.05Volume156,849 shsAverage Volume10.62 million shsMarket Capitalization$474.01 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods. Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma. The company has also developed drug-delivery technologies intended to improve the administration, absorption and targeting of therapeutics. Its technology portfolio has included Q-Sphera, a platform designed to produce long-acting injectable medicines, along with other delivery approaches for localized or sustained drug release. Biodexa is headquartered in the United Kingdom and has conducted development activities in the United States and other international markets. The company’s programs remain subject to clinical, regulatory and commercial development requirements.AI Generated. May Contain Errors. Read More Biodexa Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreBDRX MarketRank™: Biodexa Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBiodexa Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBiodexa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Biodexa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioBiodexa Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.79% of the float of Biodexa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverBiodexa Pharmaceuticals has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodexa Pharmaceuticals has recently decreased by 93.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiodexa Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiodexa Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.20 News SentimentBiodexa Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Biodexa Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for BDRX on MarketBeat in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biodexa Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.34% of the stock of Biodexa Pharmaceuticals is held by insiders.Percentage Held by Institutions17.51% of the stock of Biodexa Pharmaceuticals is held by institutions.Read more about Biodexa Pharmaceuticals' insider trading history. Receive BDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDRX Stock News HeadlinesBiodexa Pharmaceuticals Stock Set to Reverse Split on Monday, October 26th (NASDAQ:BDRX)October 10 at 1:21 AM | americanbankingnews.comBDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 PatientsSeptember 22, 2026 | finance.yahoo.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 11 at 1:00 AM | Base Camp Trading (Ad)Biodexa Enters Warrant Exercise Deal For $2 Mln As Phase 3 For ERapa Progresses; Stock Plunges 25%September 16, 2026 | rttnews.comBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross ProceedsSeptember 15, 2026 | globenewswire.comCorning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market SessionSeptember 14, 2026 | benzinga.comInterim results for the six months ended June 30, 2026September 11, 2026 | globenewswire.comBiodexa announces major milestone for its Serenta registrational Phase 3 trial in FAPAugust 19, 2026 | globenewswire.comSee More Headlines BDRX Stock Analysis - Frequently Asked Questions How have BDRX shares performed this year? Biodexa Pharmaceuticals' stock was trading at $11.35 on January 1st, 2026. Since then, BDRX shares have decreased by 95.9% and is now trading at $0.4602. How were Biodexa Pharmaceuticals' earnings last quarter? Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) released its quarterly earnings results on Thursday, September, 10th. The company reported ($80,000.00) earnings per share for the quarter. When did Biodexa Pharmaceuticals' stock split? Biodexa Pharmaceuticals's stock reverse split on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, March 18th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Biodexa Pharmaceuticals? Shares of BDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biodexa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biodexa Pharmaceuticals investors own include SoundHound AI (SOUN), Dyne Therapeutics (DYN), NVIDIA (NVDA), Viking Therapeutics (VKTX), TRACON Pharmaceuticals (TCON), ASE Technology (ASX) and BigBear.ai (BBAI). Company Calendar Last Earnings9/10/2020Today10/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 BDRX's financial health is in the Red zone, according to TradeSmith. BDRX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BDRX Previous SymbolLON:MTPH CIK1643918 Webwww.biodexapharma.com Phone441235888300FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.41 Quick RatioN/A Sales & Book Value Annual Sales$470 thousand Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book Value$110.30 per share Price / Book0.00Miscellaneous Outstanding Shares1,030,000Free Float1,026,000Market Cap$474.01 thousand OptionableNot Optionable Beta1.28 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BDRX) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
